Compare APC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | QURE |
|---|---|---|
| Founded | 2025 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.0M | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | APC | QURE |
|---|---|---|
| Price | $18.57 | $46.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $21.75 | ★ $45.00 |
| AVG Volume (30 Days) | 118.7K | ★ 2.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $4.47 | $126.12 |
| Revenue Next Year | $4.20 | $200.43 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.08 | $8.73 |
| 52 Week High | $21.72 | $71.50 |
| Indicator | APC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 79.16 |
| Support Level | $17.43 | $21.63 |
| Resistance Level | $19.43 | $60.70 |
| Average True Range (ATR) | 1.02 | 2.43 |
| MACD | -0.18 | 1.72 |
| Stochastic Oscillator | 7.12 | 84.49 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.